Weekend edition. Cash markets are shut after Friday’s payrolls; the week ahead is framed by US May CPI and, on the horizon, Warsh’s first Fed meeting (FOMC 16–17 June) into a hawkish tilt · the AI trade is still digesting Broadcom’s >$250bn hit even as the financing wave swells — the SpaceX and Anthropic IPO pipeline and a ~$420bn NextEra–Dominion power merger · the Israel–Lebanon ceasefire holds into the weekend as the US and Iran trade fresh strikes and the House votes to curb Trump’s war powers · Bitcoin extends its slide to pre-Iran lows.
Levels below are the Bloomberg Europe “Top Securities” ticker read at ~06:00 Rome — on a Sunday these are Friday’s closing levels (cash markets shut for the weekend), from the session that slipped off record highs on Broadcom’s miss. The week’s decisive events are ahead: US May CPI this week and the FOMC on 16–17 June — new Chair Kevin Warsh’s first meeting — into a Fed that has turned readier to hold, or even hike.
Top of the morning
Israel–Lebanon truce holds into the weekend — even as the US and Iran trade fresh strikes
The conditional ceasefire between Israel and Lebanon, contingent on Hezbollah standing down and reached after a Trump–Netanyahu call, is holding into the weekend — a de-escalation on one front. The wider conflict stays live: the US and Iran exchanged new strikes, and in a notable domestic check the Republican-led House voted to halt the Iran war, a rebuke of Trump’s war powers. Markets read the easing through commodities — oil eased and gold drew dip-buyers — though crude holds near $95 on residual Hormuz risk.
The AI trade is still digesting Broadcom as the IPO/financing wave swells
Broadcom’s disappointing AI-chip outlook erased more than $250bn of value and dropped the stock as much as 15%, pulling the Nasdaq and S&P 500 off record highs on Friday — the first AI-earnings stumble big enough to bite. The counter-signal stands: TSMC’s CEO warned chip supply won’t meet AI demand for years. Around the wobble the capital machine keeps building: JPMorgan is set to pitch its ultra-rich clients on the SpaceX IPO (likely the largest debut ever; UK retail demand already tops 30,000), Anthropic has lined up Morgan Stanley and Goldman, and NextEra and Dominion are planning a roughly $420bn power-utilities giant.
Hawkish Fed: Warsh’s first meeting (16–17 June) is the next big risk
Dallas Fed’s Lorie Logan said the Fed may need to raise rates this year, and the Beige Book described steady jobs alongside firmer inflation — a mix holding the 10-year near 4.48%. With Friday’s payrolls now behind the market, the next tests are US May CPI this week and Kevin Warsh’s debut FOMC on 16–17 June, which Morgan Stanley flags as a key risk for the dollar. The rate-path repricing is the quiet story under the AI noise.
Bitcoin slides to pre-Iran lows; credit cracks persist
Crypto’s slide extended over the week: Bitcoin fell to its lowest since before the Iran conflict, heading for its biggest weekly loss since late 2022, after a large Strategy (formerly MicroStrategy) sale unnerved traders. Alongside it, credit titans warned of a coming shakeout in deals that “don’t make sense,” and retail money is edging out of private credit — the clearest persistent crack under an otherwise orderly tape. Watch items for the cycle, not yet systemic events.
Europe’s big three court Putin; Washington tells allies to do more
Germany, France and the UK are sketching a plan to engage Vladimir Putin directly on Ukraine, sensing a momentum shift that strengthens Zelenskyy’s hand. In parallel, the US has told European partners to add more aircraft and vessels as it draws down its own presence — sharpening the burden-shift debate over the continent’s security.
Power and the energy transition go corporate — and political
The AI-electricity-demand theme is turning strategic. FT flags NextEra and Dominion planning a roughly $420bn utilities giant; Gates- and Nvidia-backed Commonwealth Fusion says its technology has been validated to make power; and Bloomberg’s feature on the “Iran shock” argues it is speeding Asia’s and Europe’s energy transition. The flip side is political: rising US electric bills are becoming an unusual flashpoint heading into the midterms.
Health watch: Ebola widens in DR Congo; US screwworm scare; AstraZeneca’s Europe pricing warning
A widening Ebola outbreak (Bundibugyo strain) is spreading to new areas of the DR Congo, with one infected person known to have travelled to the UAE — putting the vaccine response in focus. A deadly screwworm parasite found in US cattle is a zoonotic-risk reminder for the food chain. And on drug-pricing policy, AstraZeneca’s chief warned the group could withhold new medicines in Europe unless countries pay more for innovation — a signal for the wider pharma complex.
FT portfolio signal · tied to your holdings
What FT flagged for your book
Macro / regime read. The froth that took its first real poke on Broadcom is still being digested. With Friday’s payrolls behind the market, the swing factors now are US CPI this week and Warsh’s first FOMC (16–17 June). The myFT cluster is two-sided. Supply signals keep stacking: the editorial board warns the coming equity-supply surge (SpaceX, Anthropic) will test the AI bull run; UK retail demand for the SpaceX float already tops 30,000; tech groups are monetising AI hype by selling volatility via convertibles — a tell the market is “twitchier than usual” — and hedge funds are shorting call-centre stocks on AI disruption. The counterweights the dashboard cares about are all live: an AI-earnings / valuation test (Broadcom), a firmer-rates backdrop (Logan possible hike, Beige Book inflation, 10y ~4.48%), a crypto risk-off leg (Bitcoin’s biggest weekly loss since late 2022 after the Strategy sale), and the persistent private-credit crack (titans warn of a shakeout). War-chest deployment rules stay dormant — this is a regime tilt, not a severe trigger.
Broadcom (shelf single-name — the key one). A myFT alert frames a two-day chip sell-off threatening Wall Street’s winning streak after Broadcom’s soft revenue outlook — your direct holding sits at the epicentre of the AI-chip repricing. TSMC’s warning that supply won’t meet AI demand for years supports the long-term thesis, but near-term the miss sets a high bar for the rest of the complex.
Semiconductors (theme). Beyond Broadcom: Raspberry Pi jumped about a fifth on profitability upgrades, and the SpaceX build-out keeps the picks-and-shovels case live behind your ASML / Broadcom shelf — supply-chain and geopolitics the offset, and Broadcom a reminder the bar is now high.
AI capex / IPO supply (theme & regime). SpaceX’s record float (retail allocation lined up; it “won’t make the S&P 500”) and Anthropic’s IPO, plus the editorial-board “equity surge will test the bull run” piece, are a liquidity-absorption test for the AI mega-caps on the shelf (Microsoft, Alphabet, Amazon). More supply chasing the same AI dollars.
Energy & rates (macro regime). FT’s Unhedged flags NextEra and Dominion planning a roughly $420bn power giant — AI-electricity demand going strategic — while the weekend Chart of the Week asks whether Brent could reach $140 on an inventory drawdown, a two-sided oil signal even as spot eased on the ceasefire. With the 10y ~4.48% and a hawkish Fed, rates are the leg to respect into CPI.
Pharma / healthcare policy (theme — no core shelf single-name). AstraZeneca’s chief warned it could withhold new drugs in Europe unless countries pay more for innovation — a drug-pricing-regime signal that bears on your pharma shelf (Novo Nordisk, Eli Lilly, Vertex, UnitedHealth); plus an FT piece on investors warming to sleep biotech. No direct GLP-1 single-name alert in the window.
Consumer caution (no single-name). Robert Armstrong’s “CPG blues” flags weakness in the consumer-packaged-goods world — soft-consumer colour for the Costco / Nike / Booking discretionary corner, with no direct alert.
Shelf single-names: today’s live shelf alert is Broadcom. No GLP-1 / Novo Nordisk / Eli Lilly / Vertex / UnitedHealth / Intuitive / Visa / Mastercard / Berkshire single-name FT items in the window (AstraZeneca is a pharma-policy theme, not a shelf holding). (Name-level alerts only surface here once FT routes them to this Gmail — see the iCloud→Gmail forwarding note if they stay sparse.)
Net: the AI trade is digesting Broadcom while the capex-financing wave swells (SpaceX/Anthropic IPOs, a ~$420bn utilities merger) and the Fed leans hawkish into CPI and Warsh’s debut. Crypto risk-off and private-credit stress are the cracks. Regime: consolidation, not deploy — watch AI earnings, credit and rates.
Markets snapshot
Bloomberg Europe “Top Securities” ticker, read ~06:00 Rome on Sunday — these are Friday’s closing levels (cash markets shut for the weekend). Daily % changes are Friday’s session; oil and gold direction read from the weekend “oil dips / gold rises” market leads.
Instrument
Last (Fri close)
Change / context
S&P 500
7,553.68
−0.74% · off record on Broadcom miss
Nasdaq
26,853.97
−0.89% · AI chips led the pullback
Bloomberg 500
2,732.45
−0.77%
FTSE 100
10,332.30
−0.40% · softer with global risk
US 10-year Treasury
4.48%
yields firmer · Logan hawkish, Beige Book inflation
EUR/USD
~1.16
+0.07% · little changed
GBP/USD
~1.34
−0.04% · marginally softer
Crude Oil
$95.29
−0.76% · eased as Lebanon truce trims premium; holds ~$95
Gold (spot)
$4,489.70
+0.51% · dip-buyers return after the ceasefire
Figures transcribed from the Bloomberg Europe “Top Securities” ticker; on a weekend these are the latest (Friday) close. Equity direction confirmed against the “stocks fall from record on Broadcom” lead; oil and gold direction taken from the “oil dips” and “gold rises as dip-buyers return” stories on this morning’s homepage.
Global markets & macro
Markets closed the week in consolidation. Broadcom’s disappointing chip outlook erased more than $250bn of value and sent the stock down as much as 15%, dragging the Nasdaq (−0.89%) and S&P 500 (−0.74%) off record highs — the “more greed than fear” tape finally meeting a real stumble. Yet the AI-financing wave keeps building around it: Anthropic lined up Morgan Stanley and Goldman, JPMorgan is set to pitch SpaceX to its ultra-rich clients (UK retail demand already past 30,000), and — the freshest twist — NextEra and Dominion are planning a roughly $420bn utilities giant to ride AI-driven power demand. TSMC’s warning that chip supply won’t meet AI demand for years frames the paradox: structural demand intact, near-term expectations stretched. CrowdStrike’s soft guidance and Bitcoin’s slide to pre-Iran lows — after a large Strategy sale — round out a more cautious risk tape into the weekend.
Rates are the quieter, firmer story, and the one that matters most into the new week. Logan said the Fed may need to raise rates this year, and the Beige Book showed steady jobs but firmer inflation, holding the 10-year near 4.48%. With Friday’s payrolls now behind it, the market’s next tests are US May CPI this week and — the marquee event on the horizon — Warsh’s first FOMC on 16–17 June, which Morgan Stanley flags as a key risk for the dollar. FX stayed quiet — the euro near 1.16, sterling around 1.34. Beneath the surface, two cracks persist: private credit, where titans warn of a shakeout and retail money is edging out, and the consumer-packaged-goods “other economy” that FT’s Armstrong flags as softening. In EM, the rupiah slid toward the 18,000 level with markets braced for intervention, and Indonesia tasked its central bank with boosting “real sector” growth.
Geopolitics & world news
The Middle East is sending mixed signals, tilting toward de-escalation. The conditional Israel–Lebanon ceasefire — contingent on Hezbollah standing down, and arriving after a Trump–Netanyahu call — is holding into the weekend. But the broader conflict stays live: the US and Iran traded fresh strikes, and in a notable domestic check the Republican-led House voted to halt the Iran war, rebuking Trump’s handling of it. Markets read the balance through commodities — crude eased toward $95 as the Lebanon front cooled, while gold drew dip-buyers even with yields firm. The two-sided risk is worth holding: FT’s weekend Chart of the Week asks whether Brent could still reach $140 on an inventory drawdown, and a Bloomberg feature on the “Iran shock” accelerating Asia’s and Europe’s energy transition is the longer-run thread.
Europe’s security board is shifting too. Germany, France and the UK are sketching a plan to engage Putin directly on Ukraine, sensing a momentum shift that strengthens Zelenskyy’s hand, even as Washington tells allies to add aircraft and vessels as it draws down — sharpening the burden-shift debate. In Asia, Xi is being tested by Japan and the Philippines over Taiwan as Trump treads softly. US domestic threads run through the economy: rising electric bills are becoming a midterm flashpoint, an H-1B crackdown is denting a Texas housing boom, and the US and allies warned of a LinkedIn-based China espionage threat; in the Americas, former Mexican president López Obrador broke his silence to back Sheinbaum amid rising tensions with Washington. For the medical reader, the standouts stay clinical and biosecurity-flavoured: the Ebola outbreak (Bundibugyo strain) is widening across the DR Congo with a cross-border travel scare reaching the UAE, putting the vaccine response in focus, while a deadly screwworm parasite found in US cattle is a reminder of zoonotic risk to the food chain.
Clinical desk · NEJM current issue (4 June 2026)
This week in the New England Journal
A deeper read of the issue’s practice-relevant trials, with the numbers that matter at the bedside. (NEJM publishes weekly on Thursdays, so the 4 June issue remains current today.)
Cardiology — LAAC moves toward the anticoagulation-eligible
CHAMPION-AF randomised 3,000 AF patients who were suitable NOAC candidates (mean CHA₂DS₂-VASc 3.5) to a Watchman Flx device or a NOAC. At 3 years the composite of CV death, stroke or systemic embolism was 5.7% vs 4.8% (difference 0.9 pp, 95% CI −0.8 to 2.6) — meeting noninferiority — while non–procedure-related bleeding was roughly halved (10.9% vs 19.0%, HR 0.55), a superiority win. Caveats worth holding onto: strokes were numerically higher with the device (3.6% vs 2.5%; ischaemic stroke/systemic embolism ~0.3%/yr more), the highest-risk patients (CHA₂DS₂-VASc ≥5) were under-represented, only one device was studied, and the trial was industry-funded with an absolute (not relative) noninferiority margin. The companion editorial asks directly whether indications should now widen. Practical read: a stronger case for LAAC as a shared-decision option in bleeding-averse but anticoagulation-eligible AF — the 5-year stroke data will be the tell.
Critical care — high-flow oxygen: fewer intubations, same mortality
SOHO (42 French ICUs, 1,110 patients with P/F ≤200) found day-28 mortality identical at 14.6% vs 14.6% (P=0.98) for high-flow nasal oxygen vs standard oxygen. Intubation by day 28 was lower with high-flow (42.4% vs 48.4%, difference −5.9 pp), but serious events during spontaneous breathing (cardiac arrest or pneumothorax) were numerically more frequent (2.3% vs 1.1%). Read: this tempers the mortality rationale for HFNC; the intubation benefit persists, so the case stays individualised rather than universal.
Oncology — a step-change in pancreatic cancer
Daraxonrasib (RASolute 302). Phase 3, 500 patients with previously treated metastatic PDAC (92% RAS G12); this oral RAS(ON) inhibitor roughly doubled median overall survival vs chemotherapy (13.2 vs 6.6 months, HR 0.40, P<0.001) and improved PFS (7.3 vs 3.5 months, HR 0.45). Grade ≥3 events were actually lower than chemo (61.8% vs 69.6%) and treatment-related discontinuations far lower (1.2% vs 11.2%). In a disease where median survival is under a year, this is the standout result of the issue.
Perioperative apalutamide (PROTEUS). Phase 3, 2,109 patients, ADT ± apalutamide around radical prostatectomy. Pathological complete response / minimal residual disease rose to 8.9% vs 1.0% (OR 10.2) and 5-year metastasis-free survival to 78.2% vs 73.5% (HR 0.80, P=0.02); grade 3/4 events were higher (39.6% vs 31%, mostly rash). The first practice-changing neoadjuvant signal in prostate cancer — though the absolute MFS gain (~4.7 pp) is modest, and the editorial’s “watershed” framing is about direction more than magnitude.
Also: all-oral decitabine–cedazuridine + venetoclax gave complete responses in ~47% of newly diagnosed AML; adjuvant selpercatinib lengthened event-free survival in RET fusion–positive early-stage NSCLC.
AI in the clinic (your beat)
The governance layer is catching up to deployment. A Perspective on ambient AI documentation maps the recording-consent problem — two-party-consent states, where audio is transmitted, and the patchwork of state law that every ambient-scribe pilot now runs into — alongside an NEJM AI review on large language models in informed consent (opportunities vs thin evidence), a privacy analysis of AI scribes, and a behavioural-health letter warning that chatbot empathy can outpace accuracy. Collectively: useful tools, but consent, privacy and monitoring are the gating issues, not raw capability.
Infectious disease — ties to this morning’s Ebola thread
A correspondence characterises the 2025 Sudan virus (an ebolavirus) outbreak in Uganda, and another reports that IV artesunate still performed acceptably in children with partially artemisinin-resistant severe malaria (PfK13 mutations) — reassuring that parenteral artesunate remains usable. Directly relevant context as the markets pages flag a widening DR Congo Ebola outbreak with a cross-border travel scare.
Briefly noted
Obexelimab cut flares and glucocorticoid use in a phase-3 trial in IgG4-related disease; secukinumab hit its mark in relapsed polymyalgia rheumatica but missed in giant-cell arteritis; dual CAR T-cell desensitisation enabled kidney transplantation in two highly HLA-sensitised candidates; and a clinical-practice review distils what actually moves childhood vaccine hesitancy (clinician recommendation, presumptive framing, empathy).
Read from your open NEJM tab via Control Chrome — the current issue (4 June 2026, still current today) plus the full CHAMPION-AF, SOHO, RASolute 302 and PROTEUS abstracts. Figures summarised in original prose under copyright caution — not reproductions, and not medical advice for any individual patient.
Today & week ahead (CET)
Sun 7Weekend — Israel–Lebanon ceasefire monitoring · US–Iran strike headlines · oil on residual Hormuz risk · SpaceX IPO process (JPMorgan pitch, retail demand)
Mon 8Cash markets reopen — risk tone set by the AI-earnings read-through after Broadcom, plus credit and rates
This wkUS May CPI the next macro test after payrolls · AI-financing pipeline (SpaceX, Anthropic) · private-credit redemptions · Bitcoin’s slide · FT stock-picking competition starts Tue 9
16–17FOMC — Warsh’s first meeting as Chair (rate decision, projections, press conference); Morgan Stanley flags it as a key risk for the dollar — the marquee event on the horizon
WatchCeasefire durability · NextEra–Dominion ~$420bn merger follow-through · AI capex-vs-earnings debate · DR Congo Ebola response